LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Safety and efficacy of stenting for symptomatic intracranial artery stenosis: a systematic reveiw and meta-analysis.

    Shi, Ting / Chen, ShiJian / Long, YongPei / Gu, ZhongDeng

    Frontiers in pharmacology

    2023  Volume 14, Page(s) 1122842

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2023-06-08
    Publishing country Switzerland
    Document type Systematic Review
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2023.1122842
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Biosafety risk assessment and risk control of clinical laboratory in designated hospitals for treating COVID-19 in Chongqing, China.

    Long, Yongpei / Chang, Fan / Yang, Fangyu / Hou, Yongbin / Mo, Zhan / Diao, Qizhi

    American journal of infection control

    2022  Volume 50, Issue 9, Page(s) 999–1005

    Abstract: Background: If a nucleic acid preservation solution containing viral inactivators is used, the biosafety risk in the process of detecting the nucleic acid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be low. Patients infected ... ...

    Abstract Background: If a nucleic acid preservation solution containing viral inactivators is used, the biosafety risk in the process of detecting the nucleic acid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be low. Patients infected with SARS-CoV-2 are sent to designated hospitals for treatment in China, except for detecting nucleic acid of SARS-CoV-2, other laboratory tests such as bacterial culture may also be carried out while the patients are being treated. However, in addition to nucleic acid testing, biosafety risks in the testing of these items for patients with coronavirus disease 2019 (COVID-19) might be ignored. Therefore, we identified and evaluated risks in these detection processes and formulated appropriate, but not excessive control measures for biosafety risk, to improve the work efficiency and prevent biosafety accidents.
    Methods: Biosafety risks in all laboratory tests for COVID-19 patients were identified and evaluated according to the risk severity and occurrence probability. Subsequently, the corresponding control measures for biosafety risk were formulated according to the identified risk. Hereafter, risk monitoring was carried out.
    Results: More than 32 risks in the entire laboratory testing process were identified and evaluated, and the residual risk after the implementation of the control measures was acceptable.
    Conclusions: The biosafety risk assessment of laboratories in designated hospitals for treating COVID-19 should be re-implemented before testing specimens for COVID-19 patients. Risk management by risk monitoring is even more important, as it can prevent the occurrence of biosafety incidents and can continuously improve risk management.
    MeSH term(s) COVID-19 ; China/epidemiology ; Containment of Biohazards ; Hospitals ; Humans ; Laboratories, Clinical ; Nucleic Acids ; Risk Assessment ; SARS-CoV-2
    Chemical Substances Nucleic Acids
    Language English
    Publishing date 2022-06-05
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 392362-9
    ISSN 1527-3296 ; 0196-6553
    ISSN (online) 1527-3296
    ISSN 0196-6553
    DOI 10.1016/j.ajic.2022.05.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top